JD HEALTH

6618
34.8600.00% ( 0.000 )
Delay

News

  • HSI Closes at 23,294, Down 213 pts; HSTI Closes at 3,736, Down 21 pts; JD HEALTH Down over 15%; YIHAI INTL Hit New Highs; Market Turnover Rises

    AASTOCKS News·
    - The Hang Seng Index fell 213 points or 0.9% to close at 23,294, while the Hang Seng Tech Index dropped 21 points or 0.6% to 3,736. - Market turnover reached $177.15 billion amid a broad decline across major stock categories and key heavyweights. - JD Health experienced a sharp decline of over 15%, whereas Yihai Intl hit new highs during the trading session.
  • HSI Midday Down 266 Pts; JD HEALTH Plunges 17% Post-Results, JD-SW Drops 8%; Gold Mining Stocks Sold Off; NEW WORLD DEV Extends Decline

    AASTOCKS News·
    - The Hong Kong stock market dropped significantly during the half-day session, with the Hang Seng Index falling 266 points or 1.13% to 23,241 points. - JD-related stocks faced severe downward pressure following their quarterly results, while major tech and gold mining stocks also suffered widespread declines. - Spot gold fell below USD3,800 per ounce for the first time since September last year, prompting a broad sell-off across gold mining equities.
  • BofAS: JD HEALTH Faces Operational Volatility in 3Q but Structural Growth Remains Intact

    AASTOCKS News·
    - BofA Securities reported that JD HEALTH achieved a 17 % YoY revenue increase in 3Q, outperforming expectations despite operational volatility. - The broker expects 4Q revenue growth to slow due to regulatory scrutiny and a high base from last year's influenza outbreak, prompting a slight reduction in the full-year revenue growth forecast to 15 %. - Despite the revised near-term outlook, the broker maintains a "Buy" rating and a target price of HKD57, citing resilient earnings and ongoing structural growth.
  • JD HEALTH Collapses 13%+ as CLSA Says 3Q Results In Line, 4Q Growth Expected to Slow

    AASTOCKS News·
    - JD HEALTH plummeted over 13 % in morning trading, with the stock bottoming at HKD 35.02 amid a sharp widening of losses. - CLSA reported that the company's 3Q total revenue and adjusted EBIT rose 17 % and 14 % year-on-year to reach RMB 20 billion and RMB 1.6 billion respectively. - The broker projected a slowdown in 4Q total revenue growth to approximately 11 % year-on-year due to a milder flu season and weak consumer spending.
  • Weekly Recap | JD HEALTH -5.44%, most brokers rate it buy

    Weekly Review·
    - JD Health accumulated a 5.44% decline this week to close at 40.66 HKD, underperforming the Hang Seng Index by approximately 2.12 percentage points. - Among 17 covering institutions, 13 rated it as buy, with a consensus target price of 68.98 HKD, representing about a 69.6% premium over the current price. - Key upcoming events include the release of JD Health's Q3 fiscal 2026 financial results on November 20 and relevant macroeconomic data from Hong Kong and the US.
  • The Week Ahead: Applied Materials and Cisco Test the AI Trade as US CPI Lands Tuesday

    The Week·
    - Applied Materials and Cisco are scheduled to release earnings reports on Thursday, and the United States CPI data for October will be released on Tuesday. - US stocks recently declined amid an AI valuation test, while the Hang Seng Index rose 5.10% driven by policy statements and new listings. - Key risk variables include US-Iran negotiations, upcoming defense budget decisions, and potential Federal Reserve rate hike expectations.
  • Weekly Recap | JD HEALTH +9.63%, most brokers rate it buy

    Weekly Review·
    - JD Health cumulative rose 9.63 % to close at 43.26 HKD this week, outperforming the Hang Seng Index by about 4.98 percentage points. - The company successively signed strategic cooperation agreements with over 20 global pharmaceutical brands including Pfizer and Merck during the CIIE and launched inbound medical services. - Among 17 covering institutions, 13 rated it as buy, with a consensus target price of 68.73 HKD, while upcoming Q3 financial results will test these business developments.
  • HSI Up 739 pts; HSTI Up 188 pts; MEITUAN Up over 8%; BABA Up over 7%; XIAOMI Up over 7%; BEIGENE, CLP HOLDINGS, SWIRE PACIFIC A, SWIRE PACIFIC B Hit New Highs

    AASTOCKS News·
    - At the midday close, the Hang Seng Index rose 739 pts or 3.1% to 24,659, with the Hang Seng Tech Index and the Hang Seng China Enterprises Index also recording significant gains. - Major tech heavyweights and constituents posted strong performances, including Meituan up over 8%, and Alibaba, Xiaomi, and others climbing over 7%. - Several companies, such as BeiGene, CLP Holdings, Swire Pacific A, and Swire Pacific B, successfully hit new highs during the session.
  • JD Health climbs 5% on strategic partnership with Pfizer China

    Market Movers·
    - JD Health's stock price rose by nearly 5% during trading to reach 42.00 HKD amidst broader sector gains. - The company recently partnered strategically with Pfizer China to advance the digitalization of medical services. - Additional developments include deepened collaboration in weight management and upgraded cooperation in Hainan Boao Lecheng to promote innovative drugs and devices.
  • Niche Consolidation: Hong Kong's Specialty Leaders Forge Growth Paths Amid Fragmentation

    Global Report·
    - Hong Kong-listed specialty leaders are navigating industry challenges through strategic integration, technological upgrades, and core capabilities. - Key market players are actively expanding operations, such as WuXi XDC acquiring Toffs Pharmaceuticals for HKD 2.79 billion, JD Health launching the Zhuoyi 2.0 AI medical product, and FWD Group achieving a 90% year-on-year surge in new business annualized premiums in Hong Kong. - Additional sector activities include Paradigm Intelligent launching PhanthyCloud, Green Tea Group conducting large-scale share repurchases, and CITIC Securities issuing USD 200 million in notes to fund overseas business expansion.
  • Weekly Recap | JD HEALTH -2.49%, consensus target above spot

    Weekly Review·
    - JD Health closed the week at 37.6 HKD, marking a cumulative decline of 2.49% while outperforming the Hang Seng Index by approximately 2.03 percentage points. - Seventeen institutions have given the company a consensus rating of strong buy, with a consensus target price of 68.72 HKD, which is about 82.77% higher than its current price. - The company is scheduled to release its financial results for the third quarter of fiscal year 2026 after the market closes on November 13.